- Report
- November 2021
- 70 Pages
Global
From €3358EUR$3,500USD£2,892GBP
- Drug Pipelines
- June 2020
- 67 Pages
Global
From €3358EUR$3,500USD£2,892GBP
- Report
- October 2023
- 84 Pages
Global
From €3500EUR$3,908USD£3,120GBP
- Drug Pipelines
- August 2019
- 50 Pages
Global
From €3358EUR$3,500USD£2,892GBP
- Report
- May 2022
- 45 Pages
Global
From €2399EUR$2,500USD£2,066GBP
P2X Purinoceptors are a class of proteins found in the central nervous system (CNS) that are involved in the regulation of neurotransmission. They are activated by the binding of ATP, a nucleotide that is released from neurons during synaptic transmission. P2X Purinoceptors are involved in a variety of physiological processes, including pain perception, learning and memory, and motor control. As such, they are an important target for the development of CNS drugs.
The P2X Purinoceptor market is composed of a variety of pharmaceutical companies that are researching and developing drugs that target these receptors. These drugs are being developed for a range of indications, including pain, epilepsy, and neurodegenerative diseases. Companies in this market include AstraZeneca, GlaxoSmithKline, Merck, Pfizer, and Novartis. Show Less Read more
